Targeted Therapy

Results from the phase 1a/b TRAVERSE trial suggest that ALLO-316, an off-the-shelf CAR T-cell therapy targeting CD70, may be a promising treatment for patients with advanced clear cell renal cell carcinoma (ccRCC). The study included 51 heavily pretreated patients whose cancer had progressed after checkpoint inhibitors and VEGFR-targeted therapies. In the phase 1b group, ALLO-316 […]

Early results from the phase 1 META 10-19 trial presented at the 2026 ASCO Annual Meeting showed encouraging outcomes for patients with high-risk relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Among 14 evaluable patients treated with ultra-low doses of the IL-10–expressing anti-CD19 CAR T-cell therapy, the objective response rate was 100%, and 92.9% achieved

A new study published in Clinical Cancer Research highlights several strategies that could improve CAR T-cell therapy for pancreatic ductal adenocarcinoma (PDAC), a cancer that has remained largely resistant to immunotherapy. Researchers tested a mesothelin-targeting CAR T-cell treatment in combination with different approaches designed to overcome the tumor’s protective barriers. One strategy used aderbasib to prevent

A phase 1/1b clinical trial has shown promising results for ficerafusp alfa (BCA101) combined with pembrolizumab (Keytruda) in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Ficerafusp alfa is a first-in-class antibody that blocks both EGFR and TGF-β, two pathways linked to treatment resistance. The strongest benefit was seen in patients

Early results from the phase 1 inMMyCAR trial suggest that KLN-1010 could simplify CAR T-cell therapy for patients with relapsed or refractory multiple myeloma. Unlike traditional CAR T treatments, which require collecting and engineering a patient’s T cells in a laboratory, KLN-1010 generates anti-BCMA CAR T cells directly inside the body. This eliminates the need for

Treatment strategies for advanced pancreatic ductal adenocarcinoma (PDAC) continue to evolve, with growing emphasis on clinical trials, biomarker-driven care, and emerging targeted therapies. Current frontline treatment remains chemotherapy-based. Patients with lower performance status are typically treated with gemcitabine alone, while fitter patients may receive combination regimens such as NALIRIFOX, FOLFIRINOX, or gemcitabine plus nab-paclitaxel. Physicians

New studies highlight major progress in non-small cell lung cancer (NSCLC) treatment, particularly with targeted therapies and antibody-drug conjugates. The combination of amivantamab and lazertinib achieved a median overall survival of 41 months in treatment-naive patients with atypical EGFR-mutated NSCLC. Pumitamig, a bispecific antibody targeting PD-L1 and VEGF-A, showed a 70% response rate and 100%

Muscle-invasive bladder cancer (MIBC) treatment is undergoing major changes after nearly two decades of limited progress. Traditional treatment relied on surgery or radiation combined with cisplatin-based chemotherapy, but newer immunotherapies and targeted drugs are improving outcomes and reshaping care. Clinical trials have shown strong benefits from immune checkpoint inhibitors such as Nivolumab, Pembrolizumab, and Durvalumab.

Antibody-drug conjugates (ADCs) are changing the treatment of advanced non-small cell lung cancer (NSCLC) by delivering chemotherapy directly to cancer cells while reducing damage to healthy tissue. Doctors say these targeted therapies are showing better results than traditional second-line chemotherapy such as docetaxel, which has limited response rates. Medical oncologist Judy Wang explained that ADCs

A new targeted therapy called ozuriftamab vedotin (Oz-V) is showing strong potential for patients with advanced HPV-related throat cancer who have already tried multiple treatments. This drug is a type of antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. What makes Oz-V unique is its ability to activate only in the acidic environment